SciCombinator

Discover the most talked about and latest scientific content & concepts.

AL Lightner, LE Raffals, KL Mathis, RR Cima, CS Tse, JH Pemberton, EJ Dozois and EV Loftus
Abstract
Vedolizumab was recently FDA approved for treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD). No study to date has examined the rate of postoperative infectious complications among patients who received vedolizumab in the perioperative period. We sought to determine the 30-day postoperative infectious complication rate among IBD patients who received vedolizumab within 12 weeks of an abdominal operation as compared to patients who received TNF╬▒ inhibitors or no biologic therapy.
Tweets*
9
Facebook likes*
1
Reddit*
0
News coverage*
71
Blogs*
0
SC clicks
0
Concepts
Abdominal pain, Helminthic therapy, Biopsy, Colonoscopy, Gastroenterology, Crohn's disease, Inflammatory bowel disease, Ulcerative colitis
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com